港股異動 | 創夢天地(1119.HK)漲7.46% 宣佈將與騰訊QQ family進行合作
格隆匯3月12日丨創夢天地(1119.HK)漲7.46%,報3.89港元,總市值49億港元。昨日晚間,創夢天地(1119.HK)對外宣佈將與騰訊QQ family簽署合作協議,通過IP戰略合作共同打造中國潮娛潮玩新業態。據公吿顯示,創夢天地預計於合作協議期限的前三年內,在中國一、二線城市的熱門商業區開設合計150間直營QQ family主題線下店,而首間QQ family旗艦店擬位於深圳南山區歡樂海岸,預計將於2021年6月開業。格隆匯平台今日發佈研究文章《創夢天地(1119.HK):借力超級IP開闢第二增長曲線,打開估值空間》,可點擊鏈接參閲。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.